Bernstein Maintains a Buy Rating on Novartis (NVS), Sets a CHF108 PT

Novartis AG (NYSE:NVS) is one of the top cheap pharmaceutical stocks to buy now. In a report released on August 1, Florent Cespedes from Bernstein maintained a Buy rating on Novartis AG (NYSE:NVS) with a price target of CHF108.00.

Novartis AG (NVS): Jim Cramer Wonders Whether Its CEO Is Leaving

A doctor holding a microscope in front of a laboratory sample of healthcare products.

The rating update followed Novartis AG’s (NYSE:NVS) release of fiscal Q2 2025 results on July 17, reflecting a strong quarter with core operating income growth and double-digital sales.

Novartis AG (NYSE:NVS) reported $14.1 billion in net sales for the quarter, with volume contributing 12 percentage points to growth.

Operating income rose to $4.9 billion, primarily driven by higher net sales. Net income also grew to $4.0 billion, attributed to higher operating income.

Novartis AG (NYSE:NVS) further reported that core operating income margin was 42.2% of net sales, growing 2.6 percentage points.

Headquartered in Basel, Switzerland, Novartis AG (NYSE:NVS) develops, markets, and manufactures a range of healthcare products. Its operations span the Innovative Medicines, Sandoz, and Corporate segments.

While we acknowledge the potential of NVS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NVS and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.